Elisabetta Calistri

Learn More
Multidrug resistance is a major cause of treatment failure in acute myeloid leukemia (AML). P-glycoprotein (PGP) over-expression has an unfavorable prognostic significance, while the role of breast cancer resistance protein (BCRP) is less clear, especially in AML patients with a normal karyotype. We studied 73 consecutive AML patients with a normal(More)
Epstein-Barr virus (EBV) infection and reactivation is an increasing complication in immune deficient patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT). Therapy with anti-thymocyte globulin (ATG) is associated with higher incidence of EBV-related disease in HSCT patients, but this risk is not documented in patients(More)
Dear Editor, One of the most significant novelty of the revised version of the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia (CML) patients is that an earlier achievement of complete cytogenetic response (CCyR), at 6 months, and major molecular response (MMR), at 12months, is regarded as optimal [1]. Moreover,(More)
To assess the most important features and clinical impact of pleural effusions, which are a common toxicity during dasatinib treatment and often impair its high efficacy, 172 unselected consecutive patients with chronic myelogenous leukaemia in chronic phase treated in 27 Italian centres, with dasatinib when aged >60 years for resistance/intolerance to(More)
OBJECTIVE Chronic graft-vs-host disease (GVHD) has certain similarities with autoimmune diseases and is associated with the development of various autoantibodies in some patients. In this study, we analyzed the occurrence of autoantibodies in 63 patients surviving longer than 3 months after an allogeneic haematopoietic stem cell transplantation (HSCT), with(More)
Cytogenetic abnormalities are among the most important factors affecting the outcome of patients with acute myeloid leukaemia (AML), but approximately 40-50% of AML cases display a normal karyotype at diagnosis. Multidrug resistance (MDR) proteins overexpression is associated with worse prognosis in acute leukaemias, but its role in normal karyotype AML is(More)
Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterised by a very aggressive clinical course. Despite conventional treatment, usually intensive adriamycin-containing chemotherapy, patients affected by AITL have a poor prognosis with a median survival of less than 3 years [1]. High-dose chemotherapy with stem cell(More)
Imatinib mesylate (Glivec) is the drug of choice in newly diagnosed patients with chronic myeloid leukemia (CML) and, alone or in combination with chemotherapy, has a significant activity in Philadelphia-positive (Phþ ) acute lymphoblastic leukemia (ALL). Nonetheless, to date, allogeneic stem cell transplantation (SCT) is the only curative approach to CML.(More)
The 2013 version of the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia (CML) patients defines as optimal response the achievement of a partial cytogenetic response (PCyR) and/or BCR-ABL1 transcript ≤10% IS at 3 months, and of a complete cytogenetic response (CCyR) and/or BCR-ABL1 transcript ≤1% IS at 6 months.
BACKGROUND About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chronic illnesses. Aim of this study was to assess whether or(More)